LifeStance Health Group Q2 Earnings Call Highlights

Key Points

• Strong second-quarter performance: Revenue rose 26% year over year to $435 million, while visits increased 19% and adjusted EBITDA nearly doubled to $66 million. Free cash flow also improved to $88 million, and the company returned $49 million through share repurchases.
• Full-year guidance raised: LifeStance increased its 2026 revenue outlook to $1.685 billion–$1.725 billion, with higher Center Margin and adjusted EBITDA targets. The adjusted EBITDA midpoint implies a 13.2% margin, more than 200 basis points above the prior year.
• Investment and expansion plans: Management plans to reinvest part of its earnings outperformance in patient acquisition, technology and AI, clinician support, and specialty services such as TMS and Spravato. The company also expects a phased electronic health record transition in 2027 and will continue using tuck-in acquisitions to expand geographically.

LifeStance Health Group NASDAQ: LFST reported second-quarter results that exceeded its prior expectations, driven by higher visit volumes, increased revenue per visit and continued clinician productivity gains. The outpatient mental health provider raised its full-year revenue, Center Margin and adjusted EBITDA guidance.

Revenue rose 26% year over year to $435 million, while visit volume increased 19% to 2.6 million. Total revenue per visit increased 6% to $167. Chief Financial Officer Ryan McGroarty said the revenue outperformance reflected both stronger-than-expected visit volumes and revenue per visit.

“Our visits per average clinician were very strong once again, increasing 7% year-over-year for the third consecutive quarter,” McGroarty said. The company added 193 clinicians during the quarter, ending the period with 8,542 clinicians, up 11% from a year earlier.

Profitability and Cash Flow Improve

Center Margin increased 41% to $153 million, representing 35.2% of revenue. Adjusted EBITDA rose 94% to $66 million, or 15.2% of revenue, an improvement of more than 500 basis points from the second quarter of 2025.

LifeStance also posted net income of $24 million, compared with a loss in the prior-year period, representing a $27 million year-over-year improvement, according to McGroarty.

Free cash flow totaled $88 million, up from $57 million a year earlier. McGroarty said cash flow benefited from operating performance, collections and favorable payroll timing. He noted that payroll-related payments and the company’s annual 401(k) match, totaling roughly $60 million, are expected to affect third-quarter free cash flow.

The company ended the quarter with $226 million in cash and $259 million in net long-term debt. It reported net leverage of 0.2 times and gross leverage of 1.3 times. During the quarter, LifeStance spent $49 million on share repurchases. Its board authorized an additional $100 million repurchase program after the company used $97 million of its prior $100 million authorization.

Company Raises 2026 Outlook

LifeStance increased its full-year revenue outlook to a range of $1.685 billion to $1.725 billion, a $45 million increase at the midpoint. The midpoint implies 20% annual revenue growth.

• Center Margin guidance was raised to $570 million to $594 million, a $23 million increase at the midpoint.
• Adjusted EBITDA guidance was raised to $215 million to $235 million, a $15 million increase at the midpoint.
• The midpoint of adjusted EBITDA guidance implies a 13.2% margin, more than 200 basis points above the prior year.
• Third-quarter guidance calls for revenue of $420 million to $440 million, Center Margin of $140 million to $152 million, and adjusted EBITDA of $49 million to $59 million.

McGroarty said the updated annual forecast assumes growth primarily from higher visit volumes alongside mid-single-digit growth in revenue per visit. The company said it expects stock-based compensation of approximately $60 million to $70 million for the year.

Management said it intends to use some of its earnings outperformance to fund investments during the second half of 2026. Those investments include patient acquisition and business development, technology and artificial intelligence capabilities, clinical-excellence and outcomes teams, and expanded compensation and benefits for clinicians and certain center-support staff.

Productivity, Technology and Specialty Services

Chief Executive Officer Dave Bourdon said the company is using about 70% of the time clinicians make available, leaving room to improve utilization. He said productivity efforts include converting more prospective patients into booked appointments and optimizing clinician schedules to accommodate new-patient demand.

LifeStance plans to transition to a new electronic health record vendor in 2027. Bourdon described the project as a foundational investment intended to streamline front- and back-office operations, improve patient and clinician experiences, and provide clinicians with better data and tools. He said the implementation is expected to occur in waves and may cause a short-term productivity disruption as clinicians shift to the new platform.

The company is also expanding specialty services, including neuropsychological testing and treatment-resistant depression offerings such as transcranial magnetic stimulation, or TMS, and Spravato. Bourdon said specialty services generated about $50 million in revenue in 2025 and are expected to grow roughly 40% in 2026, with most of that growth coming from treatment-resistant depression services.

He said the pace of rollout is currently shaped mainly by LifeStance’s efforts to refine its operating model, including variations in state requirements and payer environments. The company expects to accelerate expansion in future years.

Expansion Strategy and Clinical Outcomes

LifeStance completed a small tuck-in acquisition during the quarter that expanded its therapy and psychiatry presence in Arizona. Bourdon said tuck-in acquisitions are the preferred method for entering new markets, while de novo expansion will be used where suitable acquisition targets are unavailable.

The company operates in 33 states and has a presence in roughly half of the 150 largest U.S. markets, according to management. Bourdon said acquisitions are intended primarily to establish a foundation in new geographies and are not expected to have a material effect on 2026 financial results.

On clinical outcomes, Bourdon cited company analyses showing that at least 75% of nearly 140,000 patients experienced clinically meaningful improvement in anxiety and depression symptoms across generations and geographic regions. He said LifeStance believes mental health care differentiation will increasingly be based on outcomes as well as patient access.

Management said commercial insurance remains its primary focus, although the company participates in some Medicare Advantage and exchange plans through larger payer contracts. Bourdon said the company has limited exposure to Medicaid and traditional Medicare fee-for-service.

About LifeStance Health Group (NASDAQ:LFST)

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source